nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—UGT2B15—prostate cancer	0.45	1	CbGaD
Dabigatran etexilate—CES1—Capecitabine—prostate cancer	0.113	0.421	CbGbCtD
Dabigatran etexilate—UGT2B7—Epirubicin—prostate cancer	0.0412	0.154	CbGbCtD
Dabigatran etexilate—ABCB1—Estramustine—prostate cancer	0.0228	0.085	CbGbCtD
Dabigatran etexilate—ABCB1—Cabazitaxel—prostate cancer	0.015	0.056	CbGbCtD
Dabigatran etexilate—ABCB1—Estrone—prostate cancer	0.0147	0.0548	CbGbCtD
Dabigatran etexilate—ABCB1—Ethinyl Estradiol—prostate cancer	0.0131	0.0488	CbGbCtD
Dabigatran etexilate—ABCB1—Conjugated Estrogens—prostate cancer	0.00961	0.0358	CbGbCtD
Dabigatran etexilate—ABCB1—Mitoxantrone—prostate cancer	0.00874	0.0326	CbGbCtD
Dabigatran etexilate—ABCB1—Estradiol—prostate cancer	0.00844	0.0314	CbGbCtD
Dabigatran etexilate—ABCB1—Prednisone—prostate cancer	0.00726	0.027	CbGbCtD
Dabigatran etexilate—ABCB1—Etoposide—prostate cancer	0.00551	0.0205	CbGbCtD
Dabigatran etexilate—ABCB1—Docetaxel—prostate cancer	0.00504	0.0188	CbGbCtD
Dabigatran etexilate—F2—urine—prostate cancer	0.00474	0.115	CbGeAlD
Dabigatran etexilate—ABCB1—Doxorubicin—prostate cancer	0.00376	0.014	CbGbCtD
Dabigatran etexilate—UGT2B15—prostate gland—prostate cancer	0.00311	0.0753	CbGeAlD
Dabigatran etexilate—UGT2B15—urethra—prostate cancer	0.00208	0.0504	CbGeAlD
Dabigatran etexilate—UGT2B7—prostate gland—prostate cancer	0.0019	0.046	CbGeAlD
Dabigatran etexilate—CES2—prostate gland—prostate cancer	0.0019	0.046	CbGeAlD
Dabigatran etexilate—F2—prostate gland—prostate cancer	0.0017	0.0412	CbGeAlD
Dabigatran etexilate—NQO2—prostate gland—prostate cancer	0.0017	0.0411	CbGeAlD
Dabigatran etexilate—CES2—seminal vesicle—prostate cancer	0.00161	0.0389	CbGeAlD
Dabigatran etexilate—UGT1A9—renal system—prostate cancer	0.0016	0.0389	CbGeAlD
Dabigatran etexilate—CES1—prostate gland—prostate cancer	0.00156	0.0379	CbGeAlD
Dabigatran etexilate—NQO2—seminal vesicle—prostate cancer	0.00143	0.0347	CbGeAlD
Dabigatran etexilate—CES2—renal system—prostate cancer	0.00129	0.0313	CbGeAlD
Dabigatran etexilate—UGT2B7—renal system—prostate cancer	0.00129	0.0313	CbGeAlD
Dabigatran etexilate—CES2—urethra—prostate cancer	0.00127	0.0308	CbGeAlD
Dabigatran etexilate—F2—epithelium—prostate cancer	0.00125	0.0303	CbGeAlD
Dabigatran etexilate—F2—renal system—prostate cancer	0.00116	0.0281	CbGeAlD
Dabigatran etexilate—NQO2—renal system—prostate cancer	0.00116	0.028	CbGeAlD
Dabigatran etexilate—NQO2—urethra—prostate cancer	0.00114	0.0275	CbGeAlD
Dabigatran etexilate—CES2—bone marrow—prostate cancer	0.000978	0.0237	CbGeAlD
Dabigatran etexilate—F2—bone marrow—prostate cancer	0.000877	0.0212	CbGeAlD
Dabigatran etexilate—NQO2—bone marrow—prostate cancer	0.000874	0.0212	CbGeAlD
Dabigatran etexilate—UGT2B7—testis—prostate cancer	0.000836	0.0203	CbGeAlD
Dabigatran etexilate—CES2—testis—prostate cancer	0.000836	0.0203	CbGeAlD
Dabigatran etexilate—NQO2—testis—prostate cancer	0.000747	0.0181	CbGeAlD
Dabigatran etexilate—CES1—testis—prostate cancer	0.000688	0.0167	CbGeAlD
Dabigatran etexilate—CES2—lymph node—prostate cancer	0.000606	0.0147	CbGeAlD
Dabigatran etexilate—NQO2—lymph node—prostate cancer	0.000541	0.0131	CbGeAlD
Dabigatran etexilate—CES1—lymph node—prostate cancer	0.000499	0.0121	CbGeAlD
Dabigatran etexilate—ABCB1—prostate gland—prostate cancer	0.000366	0.00887	CbGeAlD
Dabigatran etexilate—ABCB1—seminal vesicle—prostate cancer	0.00031	0.0075	CbGeAlD
Dabigatran etexilate—ABCB1—epithelium—prostate cancer	0.000269	0.00652	CbGeAlD
Dabigatran etexilate—ABCB1—renal system—prostate cancer	0.000249	0.00604	CbGeAlD
Dabigatran etexilate—ABCB1—urethra—prostate cancer	0.000245	0.00594	CbGeAlD
Dabigatran etexilate—ABCB1—bone marrow—prostate cancer	0.000189	0.00457	CbGeAlD
Dabigatran etexilate—ABCB1—testis—prostate cancer	0.000161	0.00391	CbGeAlD
Dabigatran etexilate—ABCB1—lymph node—prostate cancer	0.000117	0.00283	CbGeAlD
Dabigatran etexilate—Upper respiratory tract infection—Epirubicin—prostate cancer	4.97e-05	0.000384	CcSEcCtD
Dabigatran etexilate—Angiopathy—Prednisone—prostate cancer	4.97e-05	0.000384	CcSEcCtD
Dabigatran etexilate—Syncope—Docetaxel—prostate cancer	4.96e-05	0.000383	CcSEcCtD
Dabigatran etexilate—Pruritus—Estradiol—prostate cancer	4.96e-05	0.000383	CcSEcCtD
Dabigatran etexilate—Dysphagia—Doxorubicin—prostate cancer	4.95e-05	0.000382	CcSEcCtD
Dabigatran etexilate—Influenza—Doxorubicin—prostate cancer	4.95e-05	0.000382	CcSEcCtD
Dabigatran etexilate—Anaemia—Capecitabine—prostate cancer	4.95e-05	0.000382	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Prednisone—prostate cancer	4.95e-05	0.000382	CcSEcCtD
Dabigatran etexilate—Palpitations—Docetaxel—prostate cancer	4.88e-05	0.000377	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Docetaxel—prostate cancer	4.86e-05	0.000375	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Etoposide—prostate cancer	4.84e-05	0.000374	CcSEcCtD
Dabigatran etexilate—Cough—Docetaxel—prostate cancer	4.82e-05	0.000373	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Doxorubicin—prostate cancer	4.82e-05	0.000372	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Mitoxantrone—prostate cancer	4.81e-05	0.000371	CcSEcCtD
Dabigatran etexilate—Syncope—Capecitabine—prostate cancer	4.8e-05	0.000371	CcSEcCtD
Dabigatran etexilate—Pneumonia—Epirubicin—prostate cancer	4.8e-05	0.000371	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Estradiol—prostate cancer	4.79e-05	0.00037	CcSEcCtD
Dabigatran etexilate—Hypertension—Docetaxel—prostate cancer	4.77e-05	0.000369	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Epirubicin—prostate cancer	4.77e-05	0.000368	CcSEcCtD
Dabigatran etexilate—Infestation—Epirubicin—prostate cancer	4.77e-05	0.000368	CcSEcCtD
Dabigatran etexilate—Malnutrition—Prednisone—prostate cancer	4.77e-05	0.000368	CcSEcCtD
Dabigatran etexilate—Bronchitis—Doxorubicin—prostate cancer	4.76e-05	0.000368	CcSEcCtD
Dabigatran etexilate—Palpitations—Capecitabine—prostate cancer	4.73e-05	0.000365	CcSEcCtD
Dabigatran etexilate—Arthralgia—Docetaxel—prostate cancer	4.71e-05	0.000363	CcSEcCtD
Dabigatran etexilate—Chest pain—Docetaxel—prostate cancer	4.71e-05	0.000363	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Capecitabine—prostate cancer	4.7e-05	0.000363	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Etoposide—prostate cancer	4.69e-05	0.000362	CcSEcCtD
Dabigatran etexilate—Asthenia—Mitoxantrone—prostate cancer	4.68e-05	0.000362	CcSEcCtD
Dabigatran etexilate—Fatigue—Etoposide—prostate cancer	4.68e-05	0.000361	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	4.67e-05	0.000361	CcSEcCtD
Dabigatran etexilate—Cough—Capecitabine—prostate cancer	4.67e-05	0.000361	CcSEcCtD
Dabigatran etexilate—Constipation—Etoposide—prostate cancer	4.64e-05	0.000358	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Epirubicin—prostate cancer	4.64e-05	0.000358	CcSEcCtD
Dabigatran etexilate—Dizziness—Estradiol—prostate cancer	4.63e-05	0.000358	CcSEcCtD
Dabigatran etexilate—Hypertension—Capecitabine—prostate cancer	4.62e-05	0.000357	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Doxorubicin—prostate cancer	4.6e-05	0.000355	CcSEcCtD
Dabigatran etexilate—Arthralgia—Capecitabine—prostate cancer	4.56e-05	0.000352	CcSEcCtD
Dabigatran etexilate—Chest pain—Capecitabine—prostate cancer	4.56e-05	0.000352	CcSEcCtD
Dabigatran etexilate—Haematuria—Epirubicin—prostate cancer	4.55e-05	0.000351	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	4.52e-05	0.000349	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Epirubicin—prostate cancer	4.51e-05	0.000348	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Docetaxel—prostate cancer	4.51e-05	0.000348	CcSEcCtD
Dabigatran etexilate—Epistaxis—Epirubicin—prostate cancer	4.5e-05	0.000348	CcSEcCtD
Dabigatran etexilate—Infection—Docetaxel—prostate cancer	4.48e-05	0.000346	CcSEcCtD
Dabigatran etexilate—Sinusitis—Epirubicin—prostate cancer	4.48e-05	0.000346	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Mitoxantrone—prostate cancer	4.47e-05	0.000345	CcSEcCtD
Dabigatran etexilate—Vomiting—Estradiol—prostate cancer	4.45e-05	0.000344	CcSEcCtD
Dabigatran etexilate—Pneumonia—Doxorubicin—prostate cancer	4.44e-05	0.000343	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Etoposide—prostate cancer	4.44e-05	0.000343	CcSEcCtD
Dabigatran etexilate—Shock—Docetaxel—prostate cancer	4.44e-05	0.000343	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Docetaxel—prostate cancer	4.42e-05	0.000342	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Docetaxel—prostate cancer	4.42e-05	0.000341	CcSEcCtD
Dabigatran etexilate—Rash—Estradiol—prostate cancer	4.42e-05	0.000341	CcSEcCtD
Dabigatran etexilate—Infestation—Doxorubicin—prostate cancer	4.41e-05	0.000341	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Doxorubicin—prostate cancer	4.41e-05	0.000341	CcSEcCtD
Dabigatran etexilate—Dermatitis—Estradiol—prostate cancer	4.41e-05	0.000341	CcSEcCtD
Dabigatran etexilate—Anaemia—Prednisone—prostate cancer	4.41e-05	0.00034	CcSEcCtD
Dabigatran etexilate—Headache—Estradiol—prostate cancer	4.39e-05	0.000339	CcSEcCtD
Dabigatran etexilate—Skin disorder—Docetaxel—prostate cancer	4.38e-05	0.000338	CcSEcCtD
Dabigatran etexilate—Angioedema—Prednisone—prostate cancer	4.36e-05	0.000336	CcSEcCtD
Dabigatran etexilate—Infection—Capecitabine—prostate cancer	4.34e-05	0.000335	CcSEcCtD
Dabigatran etexilate—Urticaria—Etoposide—prostate cancer	4.31e-05	0.000333	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Epirubicin—prostate cancer	4.3e-05	0.000332	CcSEcCtD
Dabigatran etexilate—Shock—Capecitabine—prostate cancer	4.3e-05	0.000332	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Etoposide—prostate cancer	4.29e-05	0.000331	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Doxorubicin—prostate cancer	4.29e-05	0.000331	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Capecitabine—prostate cancer	4.28e-05	0.000331	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Epirubicin—prostate cancer	4.28e-05	0.000331	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Capecitabine—prostate cancer	4.28e-05	0.00033	CcSEcCtD
Dabigatran etexilate—Syncope—Prednisone—prostate cancer	4.27e-05	0.00033	CcSEcCtD
Dabigatran etexilate—Skin disorder—Capecitabine—prostate cancer	4.24e-05	0.000328	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Epirubicin—prostate cancer	4.23e-05	0.000327	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Epirubicin—prostate cancer	4.22e-05	0.000326	CcSEcCtD
Dabigatran etexilate—Hypotension—Docetaxel—prostate cancer	4.22e-05	0.000326	CcSEcCtD
Dabigatran etexilate—Haematuria—Doxorubicin—prostate cancer	4.21e-05	0.000325	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Epirubicin—prostate cancer	4.21e-05	0.000325	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Epirubicin—prostate cancer	4.2e-05	0.000324	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Prednisone—prostate cancer	4.19e-05	0.000324	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Doxorubicin—prostate cancer	4.17e-05	0.000322	CcSEcCtD
Dabigatran etexilate—Epistaxis—Doxorubicin—prostate cancer	4.16e-05	0.000322	CcSEcCtD
Dabigatran etexilate—Nausea—Estradiol—prostate cancer	4.16e-05	0.000321	CcSEcCtD
Dabigatran etexilate—Vomiting—Mitoxantrone—prostate cancer	4.15e-05	0.00032	CcSEcCtD
Dabigatran etexilate—Sinusitis—Doxorubicin—prostate cancer	4.14e-05	0.00032	CcSEcCtD
Dabigatran etexilate—Hypertension—Prednisone—prostate cancer	4.12e-05	0.000318	CcSEcCtD
Dabigatran etexilate—Rash—Mitoxantrone—prostate cancer	4.11e-05	0.000318	CcSEcCtD
Dabigatran etexilate—Dermatitis—Mitoxantrone—prostate cancer	4.11e-05	0.000317	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Docetaxel—prostate cancer	4.11e-05	0.000317	CcSEcCtD
Dabigatran etexilate—Headache—Mitoxantrone—prostate cancer	4.09e-05	0.000316	CcSEcCtD
Dabigatran etexilate—Hypotension—Capecitabine—prostate cancer	4.08e-05	0.000315	CcSEcCtD
Dabigatran etexilate—Arthralgia—Prednisone—prostate cancer	4.06e-05	0.000313	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	4.03e-05	0.000311	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Docetaxel—prostate cancer	4.02e-05	0.000311	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Etoposide—prostate cancer	4e-05	0.000309	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Doxorubicin—prostate cancer	3.98e-05	0.000308	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Capecitabine—prostate cancer	3.98e-05	0.000307	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Epirubicin—prostate cancer	3.97e-05	0.000307	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Docetaxel—prostate cancer	3.97e-05	0.000307	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Doxorubicin—prostate cancer	3.96e-05	0.000306	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Doxorubicin—prostate cancer	3.91e-05	0.000302	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Doxorubicin—prostate cancer	3.9e-05	0.000301	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Docetaxel—prostate cancer	3.89e-05	0.000301	CcSEcCtD
Dabigatran etexilate—Asthenia—Etoposide—prostate cancer	3.89e-05	0.000301	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Doxorubicin—prostate cancer	3.89e-05	0.000301	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Capecitabine—prostate cancer	3.89e-05	0.000301	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Prednisone—prostate cancer	3.89e-05	0.0003	CcSEcCtD
Dabigatran etexilate—Fatigue—Docetaxel—prostate cancer	3.89e-05	0.0003	CcSEcCtD
Dabigatran etexilate—Angiopathy—Epirubicin—prostate cancer	3.89e-05	0.0003	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Doxorubicin—prostate cancer	3.88e-05	0.0003	CcSEcCtD
Dabigatran etexilate—Nausea—Mitoxantrone—prostate cancer	3.88e-05	0.000299	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Epirubicin—prostate cancer	3.87e-05	0.000299	CcSEcCtD
Dabigatran etexilate—Infection—Prednisone—prostate cancer	3.87e-05	0.000298	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Epirubicin—prostate cancer	3.86e-05	0.000298	CcSEcCtD
Dabigatran etexilate—Constipation—Docetaxel—prostate cancer	3.86e-05	0.000298	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Capecitabine—prostate cancer	3.84e-05	0.000297	CcSEcCtD
Dabigatran etexilate—Pruritus—Etoposide—prostate cancer	3.84e-05	0.000297	CcSEcCtD
Dabigatran etexilate—Shock—Prednisone—prostate cancer	3.83e-05	0.000296	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Prednisone—prostate cancer	3.82e-05	0.000295	CcSEcCtD
Dabigatran etexilate—Skin disorder—Prednisone—prostate cancer	3.78e-05	0.000292	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Capecitabine—prostate cancer	3.77e-05	0.000291	CcSEcCtD
Dabigatran etexilate—Fatigue—Capecitabine—prostate cancer	3.77e-05	0.000291	CcSEcCtD
Dabigatran etexilate—Constipation—Capecitabine—prostate cancer	3.74e-05	0.000288	CcSEcCtD
Dabigatran etexilate—Malnutrition—Epirubicin—prostate cancer	3.73e-05	0.000288	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Etoposide—prostate cancer	3.71e-05	0.000287	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Docetaxel—prostate cancer	3.69e-05	0.000285	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Doxorubicin—prostate cancer	3.68e-05	0.000284	CcSEcCtD
Dabigatran etexilate—Flatulence—Epirubicin—prostate cancer	3.67e-05	0.000284	CcSEcCtD
Dabigatran etexilate—Back pain—Epirubicin—prostate cancer	3.61e-05	0.000279	CcSEcCtD
Dabigatran etexilate—Angiopathy—Doxorubicin—prostate cancer	3.6e-05	0.000278	CcSEcCtD
Dabigatran etexilate—Dizziness—Etoposide—prostate cancer	3.59e-05	0.000277	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Doxorubicin—prostate cancer	3.58e-05	0.000276	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Capecitabine—prostate cancer	3.57e-05	0.000276	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Doxorubicin—prostate cancer	3.57e-05	0.000276	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Docetaxel—prostate cancer	3.57e-05	0.000275	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Prednisone—prostate cancer	3.54e-05	0.000274	CcSEcCtD
Dabigatran etexilate—Urticaria—Capecitabine—prostate cancer	3.47e-05	0.000268	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Capecitabine—prostate cancer	3.45e-05	0.000267	CcSEcCtD
Dabigatran etexilate—Vomiting—Etoposide—prostate cancer	3.45e-05	0.000267	CcSEcCtD
Dabigatran etexilate—Malnutrition—Doxorubicin—prostate cancer	3.45e-05	0.000266	CcSEcCtD
Dabigatran etexilate—Anaemia—Epirubicin—prostate cancer	3.45e-05	0.000266	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Prednisone—prostate cancer	3.42e-05	0.000264	CcSEcCtD
Dabigatran etexilate—Rash—Etoposide—prostate cancer	3.42e-05	0.000264	CcSEcCtD
Dabigatran etexilate—Dermatitis—Etoposide—prostate cancer	3.42e-05	0.000264	CcSEcCtD
Dabigatran etexilate—Headache—Etoposide—prostate cancer	3.4e-05	0.000263	CcSEcCtD
Dabigatran etexilate—Flatulence—Doxorubicin—prostate cancer	3.4e-05	0.000263	CcSEcCtD
Dabigatran etexilate—Fatigue—Prednisone—prostate cancer	3.35e-05	0.000259	CcSEcCtD
Dabigatran etexilate—Syncope—Epirubicin—prostate cancer	3.34e-05	0.000258	CcSEcCtD
Dabigatran etexilate—Back pain—Doxorubicin—prostate cancer	3.34e-05	0.000258	CcSEcCtD
Dabigatran etexilate—Constipation—Prednisone—prostate cancer	3.33e-05	0.000257	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Docetaxel—prostate cancer	3.32e-05	0.000257	CcSEcCtD
Dabigatran etexilate—Palpitations—Epirubicin—prostate cancer	3.29e-05	0.000254	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Epirubicin—prostate cancer	3.28e-05	0.000253	CcSEcCtD
Dabigatran etexilate—Cough—Epirubicin—prostate cancer	3.25e-05	0.000251	CcSEcCtD
Dabigatran etexilate—Asthenia—Docetaxel—prostate cancer	3.24e-05	0.00025	CcSEcCtD
Dabigatran etexilate—Nausea—Etoposide—prostate cancer	3.22e-05	0.000249	CcSEcCtD
Dabigatran etexilate—Hypertension—Epirubicin—prostate cancer	3.22e-05	0.000249	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Capecitabine—prostate cancer	3.22e-05	0.000249	CcSEcCtD
Dabigatran etexilate—Pruritus—Docetaxel—prostate cancer	3.19e-05	0.000246	CcSEcCtD
Dabigatran etexilate—Anaemia—Doxorubicin—prostate cancer	3.19e-05	0.000246	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Prednisone—prostate cancer	3.18e-05	0.000246	CcSEcCtD
Dabigatran etexilate—Arthralgia—Epirubicin—prostate cancer	3.17e-05	0.000245	CcSEcCtD
Dabigatran etexilate—Chest pain—Epirubicin—prostate cancer	3.17e-05	0.000245	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	3.15e-05	0.000243	CcSEcCtD
Dabigatran etexilate—Asthenia—Capecitabine—prostate cancer	3.13e-05	0.000242	CcSEcCtD
Dabigatran etexilate—Syncope—Doxorubicin—prostate cancer	3.09e-05	0.000239	CcSEcCtD
Dabigatran etexilate—Urticaria—Prednisone—prostate cancer	3.09e-05	0.000239	CcSEcCtD
Dabigatran etexilate—Pruritus—Capecitabine—prostate cancer	3.09e-05	0.000239	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Docetaxel—prostate cancer	3.09e-05	0.000238	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Prednisone—prostate cancer	3.08e-05	0.000238	CcSEcCtD
Dabigatran etexilate—Palpitations—Doxorubicin—prostate cancer	3.05e-05	0.000235	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Epirubicin—prostate cancer	3.04e-05	0.000235	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Doxorubicin—prostate cancer	3.03e-05	0.000234	CcSEcCtD
Dabigatran etexilate—Infection—Epirubicin—prostate cancer	3.02e-05	0.000233	CcSEcCtD
Dabigatran etexilate—Cough—Doxorubicin—prostate cancer	3.01e-05	0.000232	CcSEcCtD
Dabigatran etexilate—Shock—Epirubicin—prostate cancer	2.99e-05	0.000231	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Capecitabine—prostate cancer	2.99e-05	0.000231	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Epirubicin—prostate cancer	2.98e-05	0.00023	CcSEcCtD
Dabigatran etexilate—Dizziness—Docetaxel—prostate cancer	2.98e-05	0.00023	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Epirubicin—prostate cancer	2.98e-05	0.00023	CcSEcCtD
Dabigatran etexilate—Hypertension—Doxorubicin—prostate cancer	2.98e-05	0.00023	CcSEcCtD
Dabigatran etexilate—Skin disorder—Epirubicin—prostate cancer	2.96e-05	0.000228	CcSEcCtD
Dabigatran etexilate—Arthralgia—Doxorubicin—prostate cancer	2.94e-05	0.000227	CcSEcCtD
Dabigatran etexilate—Chest pain—Doxorubicin—prostate cancer	2.94e-05	0.000227	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	2.92e-05	0.000225	CcSEcCtD
Dabigatran etexilate—Dizziness—Capecitabine—prostate cancer	2.89e-05	0.000223	CcSEcCtD
Dabigatran etexilate—Vomiting—Docetaxel—prostate cancer	2.87e-05	0.000222	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Prednisone—prostate cancer	2.87e-05	0.000221	CcSEcCtD
Dabigatran etexilate—Rash—Docetaxel—prostate cancer	2.84e-05	0.00022	CcSEcCtD
Dabigatran etexilate—Hypotension—Epirubicin—prostate cancer	2.84e-05	0.00022	CcSEcCtD
Dabigatran etexilate—Dermatitis—Docetaxel—prostate cancer	2.84e-05	0.000219	CcSEcCtD
Dabigatran etexilate—Headache—Docetaxel—prostate cancer	2.83e-05	0.000218	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Doxorubicin—prostate cancer	2.82e-05	0.000217	CcSEcCtD
Dabigatran etexilate—Infection—Doxorubicin—prostate cancer	2.8e-05	0.000216	CcSEcCtD
Dabigatran etexilate—Asthenia—Prednisone—prostate cancer	2.79e-05	0.000216	CcSEcCtD
Dabigatran etexilate—Vomiting—Capecitabine—prostate cancer	2.78e-05	0.000214	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Epirubicin—prostate cancer	2.77e-05	0.000214	CcSEcCtD
Dabigatran etexilate—Shock—Doxorubicin—prostate cancer	2.77e-05	0.000214	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Doxorubicin—prostate cancer	2.76e-05	0.000213	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Doxorubicin—prostate cancer	2.76e-05	0.000213	CcSEcCtD
Dabigatran etexilate—Rash—Capecitabine—prostate cancer	2.75e-05	0.000213	CcSEcCtD
Dabigatran etexilate—Pruritus—Prednisone—prostate cancer	2.75e-05	0.000213	CcSEcCtD
Dabigatran etexilate—Dermatitis—Capecitabine—prostate cancer	2.75e-05	0.000212	CcSEcCtD
Dabigatran etexilate—Headache—Capecitabine—prostate cancer	2.74e-05	0.000211	CcSEcCtD
Dabigatran etexilate—Skin disorder—Doxorubicin—prostate cancer	2.73e-05	0.000211	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Epirubicin—prostate cancer	2.71e-05	0.00021	CcSEcCtD
Dabigatran etexilate—Nausea—Docetaxel—prostate cancer	2.68e-05	0.000207	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Epirubicin—prostate cancer	2.68e-05	0.000207	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Prednisone—prostate cancer	2.66e-05	0.000206	CcSEcCtD
Dabigatran etexilate—Hypotension—Doxorubicin—prostate cancer	2.63e-05	0.000203	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Epirubicin—prostate cancer	2.63e-05	0.000203	CcSEcCtD
Dabigatran etexilate—Fatigue—Epirubicin—prostate cancer	2.62e-05	0.000203	CcSEcCtD
Dabigatran etexilate—Constipation—Epirubicin—prostate cancer	2.6e-05	0.000201	CcSEcCtD
Dabigatran etexilate—Nausea—Capecitabine—prostate cancer	2.59e-05	0.0002	CcSEcCtD
Dabigatran etexilate—Dizziness—Prednisone—prostate cancer	2.57e-05	0.000199	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.57e-05	0.000198	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Doxorubicin—prostate cancer	2.51e-05	0.000194	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Epirubicin—prostate cancer	2.49e-05	0.000192	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Doxorubicin—prostate cancer	2.48e-05	0.000191	CcSEcCtD
Dabigatran etexilate—Vomiting—Prednisone—prostate cancer	2.47e-05	0.000191	CcSEcCtD
Dabigatran etexilate—Rash—Prednisone—prostate cancer	2.45e-05	0.000189	CcSEcCtD
Dabigatran etexilate—Dermatitis—Prednisone—prostate cancer	2.45e-05	0.000189	CcSEcCtD
Dabigatran etexilate—Headache—Prednisone—prostate cancer	2.44e-05	0.000188	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.43e-05	0.000188	CcSEcCtD
Dabigatran etexilate—Fatigue—Doxorubicin—prostate cancer	2.43e-05	0.000187	CcSEcCtD
Dabigatran etexilate—Urticaria—Epirubicin—prostate cancer	2.42e-05	0.000187	CcSEcCtD
Dabigatran etexilate—Constipation—Doxorubicin—prostate cancer	2.41e-05	0.000186	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Epirubicin—prostate cancer	2.41e-05	0.000186	CcSEcCtD
Dabigatran etexilate—Nausea—Prednisone—prostate cancer	2.31e-05	0.000178	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Doxorubicin—prostate cancer	2.3e-05	0.000178	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Epirubicin—prostate cancer	2.24e-05	0.000173	CcSEcCtD
Dabigatran etexilate—Urticaria—Doxorubicin—prostate cancer	2.24e-05	0.000173	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Doxorubicin—prostate cancer	2.23e-05	0.000172	CcSEcCtD
Dabigatran etexilate—Asthenia—Epirubicin—prostate cancer	2.18e-05	0.000169	CcSEcCtD
Dabigatran etexilate—Pruritus—Epirubicin—prostate cancer	2.15e-05	0.000166	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Epirubicin—prostate cancer	2.08e-05	0.000161	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Doxorubicin—prostate cancer	2.07e-05	0.00016	CcSEcCtD
Dabigatran etexilate—Asthenia—Doxorubicin—prostate cancer	2.02e-05	0.000156	CcSEcCtD
Dabigatran etexilate—Dizziness—Epirubicin—prostate cancer	2.01e-05	0.000155	CcSEcCtD
Dabigatran etexilate—Pruritus—Doxorubicin—prostate cancer	1.99e-05	0.000154	CcSEcCtD
Dabigatran etexilate—Vomiting—Epirubicin—prostate cancer	1.93e-05	0.000149	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Doxorubicin—prostate cancer	1.93e-05	0.000149	CcSEcCtD
Dabigatran etexilate—Rash—Epirubicin—prostate cancer	1.92e-05	0.000148	CcSEcCtD
Dabigatran etexilate—Dermatitis—Epirubicin—prostate cancer	1.92e-05	0.000148	CcSEcCtD
Dabigatran etexilate—Headache—Epirubicin—prostate cancer	1.91e-05	0.000147	CcSEcCtD
Dabigatran etexilate—Dizziness—Doxorubicin—prostate cancer	1.86e-05	0.000144	CcSEcCtD
Dabigatran etexilate—Nausea—Epirubicin—prostate cancer	1.81e-05	0.00014	CcSEcCtD
Dabigatran etexilate—Vomiting—Doxorubicin—prostate cancer	1.79e-05	0.000138	CcSEcCtD
Dabigatran etexilate—Rash—Doxorubicin—prostate cancer	1.78e-05	0.000137	CcSEcCtD
Dabigatran etexilate—Dermatitis—Doxorubicin—prostate cancer	1.77e-05	0.000137	CcSEcCtD
Dabigatran etexilate—Headache—Doxorubicin—prostate cancer	1.76e-05	0.000136	CcSEcCtD
Dabigatran etexilate—Nausea—Doxorubicin—prostate cancer	1.67e-05	0.000129	CcSEcCtD
Dabigatran etexilate—F2—Metabolism of proteins—CXCL8—prostate cancer	5.54e-06	5.02e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—RXRA—prostate cancer	5.53e-06	5.01e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—prostate cancer	5.5e-06	4.99e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—NCOA2—prostate cancer	5.49e-06	4.97e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CG—prostate cancer	5.49e-06	4.97e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CASP9—prostate cancer	5.43e-06	4.92e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—TNFRSF21—prostate cancer	5.36e-06	4.86e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—SLC5A5—prostate cancer	5.35e-06	4.84e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—COMT—prostate cancer	5.33e-06	4.82e-05	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CD—prostate cancer	5.31e-06	4.81e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GSTP1—prostate cancer	5.3e-06	4.8e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PRKCQ—prostate cancer	5.26e-06	4.76e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NGFR—prostate cancer	5.26e-06	4.76e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PTEN—prostate cancer	5.26e-06	4.76e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TGFB1—prostate cancer	5.25e-06	4.76e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC5A5—prostate cancer	5.24e-06	4.74e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP2E1—prostate cancer	5.22e-06	4.73e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP7B1—prostate cancer	5.22e-06	4.73e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—MTAP—prostate cancer	5.22e-06	4.73e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ITPR1—prostate cancer	5.22e-06	4.72e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—prostate cancer	5.21e-06	4.72e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MAP3K7—prostate cancer	5.2e-06	4.71e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—NQO1—prostate cancer	5.16e-06	4.68e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—CTNNB1—prostate cancer	5.11e-06	4.63e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—prostate cancer	5.11e-06	4.63e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—TH—prostate cancer	5.09e-06	4.61e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SULT1E1—prostate cancer	5.09e-06	4.61e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SRD5A1—prostate cancer	5.09e-06	4.61e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	5.06e-06	4.58e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP3A4—prostate cancer	5.04e-06	4.56e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—EP300—prostate cancer	5.01e-06	4.54e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	5.01e-06	4.54e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FGF10—prostate cancer	5e-06	4.53e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—prostate cancer	4.97e-06	4.51e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP1B1—prostate cancer	4.95e-06	4.48e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ADRB2—prostate cancer	4.94e-06	4.48e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—TYMS—prostate cancer	4.93e-06	4.46e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—prostate cancer	4.93e-06	4.46e-05	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—JAK2—prostate cancer	4.88e-06	4.42e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GSTM1—prostate cancer	4.87e-06	4.41e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—KRAS—prostate cancer	4.86e-06	4.41e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—MAP2K1—prostate cancer	4.86e-06	4.4e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ACSL4—prostate cancer	4.85e-06	4.39e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—HSD17B3—prostate cancer	4.85e-06	4.39e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CD—prostate cancer	4.83e-06	4.37e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—VAV3—prostate cancer	4.82e-06	4.37e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—prostate cancer	4.81e-06	4.36e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—prostate cancer	4.8e-06	4.35e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GGT1—prostate cancer	4.8e-06	4.34e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—LPL—prostate cancer	4.78e-06	4.33e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TGFBR2—prostate cancer	4.75e-06	4.3e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—NCOA1—prostate cancer	4.72e-06	4.28e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ITPR1—prostate cancer	4.68e-06	4.24e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP19A1—prostate cancer	4.66e-06	4.22e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PHGDH—prostate cancer	4.65e-06	4.21e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ARG2—prostate cancer	4.65e-06	4.21e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—UMPS—prostate cancer	4.65e-06	4.21e-05	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CB—prostate cancer	4.63e-06	4.2e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—NCOA1—prostate cancer	4.63e-06	4.19e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CYP1A1—prostate cancer	4.62e-06	4.18e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ERCC2—prostate cancer	4.58e-06	4.15e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—prostate cancer	4.58e-06	4.15e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—LDHB—prostate cancer	4.56e-06	4.13e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—RXRA—prostate cancer	4.49e-06	4.07e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP3A5—prostate cancer	4.48e-06	4.06e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IGF1R—prostate cancer	4.47e-06	4.05e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PIK3CA—prostate cancer	4.47e-06	4.05e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—prostate cancer	4.45e-06	4.03e-05	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CXCL8—prostate cancer	4.45e-06	4.03e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—JAK2—prostate cancer	4.43e-06	4.01e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—RXRA—prostate cancer	4.4e-06	3.99e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	4.37e-06	3.96e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—prostate cancer	4.34e-06	3.93e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—COMT—prostate cancer	4.33e-06	3.92e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—TCN2—prostate cancer	4.32e-06	3.92e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTA3—prostate cancer	4.32e-06	3.92e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PDHA1—prostate cancer	4.32e-06	3.92e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—UCP3—prostate cancer	4.32e-06	3.92e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TP53—prostate cancer	4.32e-06	3.92e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSTP1—prostate cancer	4.31e-06	3.9e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—MTHFR—prostate cancer	4.3e-06	3.9e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—LPL—prostate cancer	4.29e-06	3.88e-05	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—IL2—prostate cancer	4.25e-06	3.85e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PDGFRB—prostate cancer	4.25e-06	3.85e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ITPR1—prostate cancer	4.24e-06	3.84e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PPARA—prostate cancer	4.22e-06	3.83e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CB—prostate cancer	4.21e-06	3.81e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	4.17e-06	3.77e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ITGB3—prostate cancer	4.14e-06	3.75e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—HSD3B1—prostate cancer	4.12e-06	3.74e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SLC22A3—prostate cancer	4.12e-06	3.74e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CXCL8—prostate cancer	4.04e-06	3.66e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ERBB3—prostate cancer	4.02e-06	3.64e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FGFR2—prostate cancer	4.01e-06	3.63e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—TYMS—prostate cancer	4e-06	3.63e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—prostate cancer	3.99e-06	3.61e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—prostate cancer	3.98e-06	3.6e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CAV1—prostate cancer	3.97e-06	3.6e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSTM1—prostate cancer	3.96e-06	3.59e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—TBXAS1—prostate cancer	3.95e-06	3.58e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTA4—prostate cancer	3.95e-06	3.58e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—prostate cancer	3.9e-06	3.53e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—LPL—prostate cancer	3.89e-06	3.52e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL2—prostate cancer	3.86e-06	3.5e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTA2—prostate cancer	3.85e-06	3.49e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TERT—prostate cancer	3.85e-06	3.49e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ABCG5—prostate cancer	3.81e-06	3.45e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SULT1A1—prostate cancer	3.81e-06	3.45e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP1A1—prostate cancer	3.75e-06	3.4e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ERCC2—prostate cancer	3.72e-06	3.37e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTA1—prostate cancer	3.72e-06	3.37e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PIK3CA—prostate cancer	3.71e-06	3.36e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—prostate cancer	3.69e-06	3.34e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HIF1A—prostate cancer	3.68e-06	3.33e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NAT2—prostate cancer	3.68e-06	3.33e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—HSD3B2—prostate cancer	3.68e-06	3.33e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTO1—prostate cancer	3.68e-06	3.33e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—AKT1—prostate cancer	3.65e-06	3.31e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CG—prostate cancer	3.62e-06	3.28e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—LEP—prostate cancer	3.59e-06	3.25e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CAV1—prostate cancer	3.56e-06	3.22e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PLCB2—prostate cancer	3.52e-06	3.19e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—LRP2—prostate cancer	3.52e-06	3.19e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP2C18—prostate cancer	3.52e-06	3.19e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KDR—prostate cancer	3.52e-06	3.19e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—MTHFR—prostate cancer	3.5e-06	3.17e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—P4HB—prostate cancer	3.46e-06	3.13e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PPARA—prostate cancer	3.43e-06	3.11e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ESR1—prostate cancer	3.43e-06	3.11e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—INS—prostate cancer	3.42e-06	3.1e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—prostate cancer	3.39e-06	3.07e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SLC22A1—prostate cancer	3.36e-06	3.05e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—PPARA—prostate cancer	3.36e-06	3.04e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CREBBP—prostate cancer	3.35e-06	3.04e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—BAD—prostate cancer	3.35e-06	3.03e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SULT2A1—prostate cancer	3.28e-06	2.97e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—prostate cancer	3.28e-06	2.97e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CG—prostate cancer	3.24e-06	2.94e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—APC—prostate cancer	3.24e-06	2.94e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CAV1—prostate cancer	3.23e-06	2.92e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—MED12—prostate cancer	3.22e-06	2.92e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EGF—prostate cancer	3.21e-06	2.9e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IRS1—prostate cancer	3.21e-06	2.9e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GNG5—prostate cancer	3.2e-06	2.9e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CD—prostate cancer	3.18e-06	2.88e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GSK3B—prostate cancer	3.11e-06	2.82e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.08e-06	2.79e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NCOA3—prostate cancer	3.08e-06	2.79e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—INS—prostate cancer	3.07e-06	2.78e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—AKT1—prostate cancer	3.03e-06	2.74e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CREBBP—prostate cancer	3.01e-06	2.72e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—NOS3—prostate cancer	3e-06	2.72e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IGF1—prostate cancer	2.97e-06	2.69e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—EGFR—prostate cancer	2.95e-06	2.68e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—HPGDS—prostate cancer	2.94e-06	2.66e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CG—prostate cancer	2.94e-06	2.66e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP2C19—prostate cancer	2.92e-06	2.65e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MAP2K1—prostate cancer	2.87e-06	2.6e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CD—prostate cancer	2.85e-06	2.58e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ACHE—prostate cancer	2.85e-06	2.58e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTT1—prostate cancer	2.85e-06	2.58e-05	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CA—prostate cancer	2.82e-06	2.56e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SERPINE1—prostate cancer	2.82e-06	2.55e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP2A6—prostate cancer	2.82e-06	2.55e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—KRAS—prostate cancer	2.79e-06	2.53e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—INS—prostate cancer	2.78e-06	2.52e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CB—prostate cancer	2.77e-06	2.51e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	2.77e-06	2.51e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PTGS2—prostate cancer	2.75e-06	2.49e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—AKR1C3—prostate cancer	2.74e-06	2.48e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FGF2—prostate cancer	2.73e-06	2.47e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PRKACB—prostate cancer	2.73e-06	2.47e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CREBBP—prostate cancer	2.72e-06	2.47e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP17A1—prostate cancer	2.7e-06	2.44e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NOS3—prostate cancer	2.69e-06	2.44e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—CREBBP—prostate cancer	2.67e-06	2.42e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—JAK2—prostate cancer	2.62e-06	2.37e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CD—prostate cancer	2.58e-06	2.34e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NCOA2—prostate cancer	2.57e-06	2.33e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CA—prostate cancer	2.56e-06	2.32e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MDM2—prostate cancer	2.55e-06	2.31e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ERBB2—prostate cancer	2.52e-06	2.28e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CB—prostate cancer	2.48e-06	2.25e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SLC5A5—prostate cancer	2.45e-06	2.22e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—NOS3—prostate cancer	2.44e-06	2.21e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP2E1—prostate cancer	2.4e-06	2.17e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PTEN—prostate cancer	2.39e-06	2.17e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CXCL8—prostate cancer	2.39e-06	2.16e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NQO1—prostate cancer	2.37e-06	2.15e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—TH—prostate cancer	2.33e-06	2.11e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CDKN1B—prostate cancer	2.33e-06	2.11e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP3A4—prostate cancer	2.31e-06	2.09e-05	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—AKT1—prostate cancer	2.31e-06	2.09e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CASP3—prostate cancer	2.29e-06	2.07e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—EP300—prostate cancer	2.28e-06	2.07e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL2—prostate cancer	2.28e-06	2.07e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP1B1—prostate cancer	2.27e-06	2.06e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL6—prostate cancer	2.27e-06	2.06e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CB—prostate cancer	2.25e-06	2.04e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PTGS2—prostate cancer	2.23e-06	2.02e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCND1—prostate cancer	2.22e-06	2.01e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CTNNB1—prostate cancer	2.2e-06	2e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GGT1—prostate cancer	2.2e-06	1.99e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NCOA1—prostate cancer	2.17e-06	1.96e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MMP9—prostate cancer	2.16e-06	1.96e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CDKN1A—prostate cancer	2.15e-06	1.95e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTEN—prostate cancer	2.15e-06	1.94e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP19A1—prostate cancer	2.14e-06	1.93e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—AKT1—prostate cancer	2.09e-06	1.9e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—RXRA—prostate cancer	2.06e-06	1.87e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EP300—prostate cancer	2.05e-06	1.85e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SRC—prostate cancer	1.99e-06	1.8e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—COMT—prostate cancer	1.99e-06	1.8e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTP1—prostate cancer	1.98e-06	1.79e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PTEN—prostate cancer	1.95e-06	1.76e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ITPR1—prostate cancer	1.94e-06	1.76e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—VEGFA—prostate cancer	1.94e-06	1.76e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—STAT3—prostate cancer	1.92e-06	1.74e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—EP300—prostate cancer	1.86e-06	1.68e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—TYMS—prostate cancer	1.84e-06	1.66e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTM1—prostate cancer	1.82e-06	1.64e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MYC—prostate cancer	1.78e-06	1.62e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—LPL—prostate cancer	1.78e-06	1.61e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TGFB1—prostate cancer	1.78e-06	1.61e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EGFR—prostate cancer	1.75e-06	1.58e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP1A1—prostate cancer	1.72e-06	1.56e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ERCC2—prostate cancer	1.71e-06	1.55e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CA—prostate cancer	1.69e-06	1.53e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KRAS—prostate cancer	1.65e-06	1.49e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—MTHFR—prostate cancer	1.6e-06	1.45e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PPARA—prostate cancer	1.57e-06	1.43e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CA—prostate cancer	1.51e-06	1.37e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CAV1—prostate cancer	1.48e-06	1.34e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TP53—prostate cancer	1.47e-06	1.33e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—AKT1—prostate cancer	1.38e-06	1.25e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CA—prostate cancer	1.37e-06	1.24e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CG—prostate cancer	1.35e-06	1.22e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL6—prostate cancer	1.34e-06	1.21e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—INS—prostate cancer	1.28e-06	1.16e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CREBBP—prostate cancer	1.25e-06	1.13e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AKT1—prostate cancer	1.24e-06	1.12e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CD—prostate cancer	1.19e-06	1.07e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—AKT1—prostate cancer	1.12e-06	1.02e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NOS3—prostate cancer	1.12e-06	1.01e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CB—prostate cancer	1.03e-06	9.36e-06	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTGS2—prostate cancer	1.02e-06	9.27e-06	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTEN—prostate cancer	8.93e-07	8.09e-06	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—EP300—prostate cancer	8.51e-07	7.71e-06	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CA—prostate cancer	6.3e-07	5.7e-06	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—AKT1—prostate cancer	5.14e-07	4.66e-06	CbGpPWpGaD
